Navigation Links
PDL BioPharma to Announce Third Quarter 2012 Financial Results on November 5, 2012
Date:11/1/2012

INCLINE VILLAGE, Nev., Nov. 1, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its third quarter financial results for the period ended September 30, 2012, on Monday, November 5, 2012, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results.  A slide presentation relating to the call will be available via the webcast link on the PDL website.

(Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO)

Conference Call Details

To access the live conference call via phone, please dial (877) 303-9145 from the United States and Canada or (760) 536-5203 internationally. The conference ID is 55617262. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through November 12, 2012, and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 55617262.

To access the live and subsequently archived webcast of the conference call, go to the Company's website at http://www.pdl.com and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new revenue generating assets and maximizing value for its shareholders. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
2. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
3. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
4. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
5. Genesis Biopharma Announces Termination of Previously Announced Proposed Public Offering
6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
7. S1 Biopharma Expands Focus to Include Male Sexual Health
8. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
9. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
10. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
11. Galena Biopharma, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , Tenn. and DALLAS , April 19, ... Inc., announced that the first patients in ... EndoStim device in the Lower Esophageal Sphincter Stimulation for ... minimally-invasive implantable device designed to provide long-term reflux control ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-naïve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce ... process has been in place since the RBMA was founded in 1968 with all ... Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... and College of Urgent Care Medicine will host industry leaders for the annual ... will help those in the industry adapt to the issues currently affecting urgent ...
(Date:4/28/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has ... which He does not. Yisrayl says with so many titles and names for the ... he says with a little Scripture, backed with a lot of research, the truth is ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... skincare and advanced nutraceutical supplements, through its Nova Skin Sciences division, recently ... hydrating benefits of a moisturizer with the power of an anti-aging concentrate. ...
(Date:4/28/2017)... ... 2017 , ... Christie Medical Holdings, Inc. , with its market-leading ... Medical Inc. , a leader in infusion therapy and pain management. , Intravenous ... percent of hospital patients receiving a peripheral IV catheter as part of their treatment ...
Breaking Medicine News(10 mins):